Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update
NORCROSS, Ga., May 15, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:…
Alamar Biosciences Announces the Launch of the NULISAseq Mouse Panel 120
Providing the largest and most comprehensive, high sensitivity, protein biomarker analysis to…
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for Revuforj (revumenib)
LOUISVILLE, Ky., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading…